Evidence has been shown that S100P protein could mediate these processes by binding of Ca2+ ions, receptor for advanced glycation end products, cytoskeletal protein ezrin, calcyclin-binding protein/Siah-1-interacting protein and cathepsin D. Additionally, S100P could be applied as diagnostic marker, therapy target and prognostic/predictive indicator in a variety of different tumor types 94, 98. The gene discussed is S100P; the disease is neoplasm.